The Keller Laboratory at cc-TDI

Monday, December 8, 2014

Be a Dog's Best Friend

Can finding new treatments for dogs with soft tissue sarcomas also help develop new drugs for children and adults with soft tissue sarcomas? This possibility is raised by today's publication by collaborator Milan Milovance entitled, Comparative Pathology of Canine Soft Tissue Sarcomas: Possible Models of Human Non-rhabdomyosarcoma Soft Tissue Sarcoma. Co-authors of this study include Charles, as well as long time collaborator adult sarcoma pathologist, Atiya Mansoor. [ pictured: undifferentiated sarcoma (also called UPS, or MFH) in dog and human ]

Saturday, December 6, 2014

The Art of Survivorship

This month the collection, "Mother & Son: The Art of a Mom’s Journey through Childhood Cancer with Her Son" will be on display at Tiny’s Coffee 1412 SE 12th Portland, Oregon. The artist, April, is an advocate for childhood cancer survivorship, her son now thriving after a challenging period with sarcoma. The mixed media of paint-on-radiograph is accompanied by the history, from a mother's perspective, of the experience.

Friday, October 31, 2014

AACR Pediatric Cancer Think-Tank

This week the AACR held a think-tank in Philadelphia on the critical issues in childhood cancer research and care delivery. In attendance were 43 invitees from universities, pharmaceutical companies and patient advocacy groups. Topics included prevention (yes, prevention!), improved care for hereditable cancer predispositions, making drugs available for children with cancer, and the promise of genomics in delivering personalized cancer care. Charles presented on the topic that not only mutation but also cell of origin strongy influences response to treatment - and the types of epigenetic therapies that can be given.

Monday, October 20, 2014

exciting news

How much is a tumor like a wound? Will tumor cells interact with the body's normal muscle stem cells, co-opting them for advantage to the tumor? Can IL-4 Receptor antibodies block this process? These are the questions in our NIH R01 grant application that was scored this week in the top 4% of grants for that review cycle (usually, the top 9% of grants are funded). We're very excited about this grant, and the probable 5 years of funding to pursue these question that we think will benefit patients with rhabdomyosarcoma in a tangible way. Kudos to Megan, who took strong work by Imran, Tohru and GH to the next level and made this project possible.

Tuesday, October 7, 2014

SARC SPORE meeting

We presented our research project in collaboration with Dr. David Langenau (MGH) at today's SARC clinical trial consortium SPORE meeting - we are grateful for this 2 year pilot project funding. Differentiation as a therapy for rhabdomyosarcoma? possibly!

Friday, October 3, 2014

upcoming lab participation & talks

AACR Pediatric Cancer Think Tank (October 2014)
Pablove Foundation Pediatric Soft Tissue Sarcoma Symposium Think Tank (November 2014)
AACR Recent Advances Sessions (April 2015)
AACR Special Conference on The Basic Science of Sarcomas (November 2015)

Sunday, September 21, 2014

Children's Oncology Group Fall Meeting

This meeting was productive. Our lab presented at the Soft Tissue Sarcoma Chemotherapy Breakout session on "Three novel target-therapy pairs for potential clinical trials within 18 months?", as well as at the CNS session on "Ad Hoc Preclinical Consortia to Support Trial Design". Both presentations bridged scientific/drug discovery and the potential initiation of clinical trials.

You Can Participate in our Novel Therapeutics Studies !

One would like to think that tangibly better treatments for rhabdomyosarcoma, medulloblastoma and other childhood cancers can be found in a matter of years, instead of tens of years. Finding new treatments starts with research, perhaps even a new research approach to identifying effective new treatments. The Children's Cancer Therapy Development Institute focuses on finding molecules in childhood cancers that can be directly turned off or on by drugs so that the tumor stops growing. Behind our novel approach is the use of genetically-engineered mice. Our Pediatric Preclinical Testing Initiative uses mice modified from before birth so that at a certain age, and in a certain tissue, the same mutations found in a child’s cancer are activated in the mouse. These special mouse models of childhood cancer can be used to test a treatment to see whether the tumor growth and spread (metastasis) can be reversed. The specific aspect of these mice having normal immune systems is a real plus, too, because white blood cells play an important role in how tumors evolve and respond to therapy.

Our program is designed around community participation. Through the Children's Cancer Therapy Development Institute, you can contribute directly to this grass-roots initiative. Donations through small gifts or grants will assist in studying compounds that may be effective in treating such childhood cancers as alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, or medulloblastoma (the alveolar rhabdomyosarcoma model was featured by Dr. Keller's long time collaborator and former mentor, 2007 Nobel laureate Mario Capecchi, in his Nobel Prize lecture {see 16 minutes onward}.)

For additional information regarding supporting this program please contact Charles Keller at charles@cc-tdi.org. Results obtained through these studies will be shared with the National Cancer Institute’s Cancer Therapy Evaluation Program, as well as the Children’s Oncology Group, which designs clinical trials for childhood cancer.